Abstract
One of the main pathological characteristics of Alzheimers disease is the presence in the brain of the patients of an aberrant structure, the paired helical filaments, composed of hyperphosphorylated tau. The level of tau phosphorylation has been correlated with the capacity for tau aggregation. Thus, the mechanism for tau phosphorylation could be important to clarify those pathological features in Alzheimers disease. Tau protein could be modified by different kinases, being GSK3 the one that could modify more sites of that protein. GSK3 activity could be modulate by the presence of metals like magnesium that can be required for the proper function of the kinase, whereas, metals like manganesum or lithium inhibit the activity of the kinase. Many works have been done to study the inhibition of GSK3 by lithium, a specific inhibitor of that kinase. More recently, it has been indicated that sodium tungstate could also inhibit GSK3 through a different mechanism. In this review, we discuss the effect of these two metals, lithium and tungstate, on GSK3 (or tau I kinase) activity.
Keywords: tau kinase, GSK3 inhibition, insulin degrading enzyme (IDE), glycogen synthase (GS), Alzheimer, ’, s disease
Current Alzheimer Research
Title: Inhibition of GSK3 Dependent Tau Phosphorylation by Metals
Volume: 3 Issue: 2
Author(s): Alberto Gomez-Ramos, Jorge Dominguez, Delia Zafra, Helena Corominola, Ramon Gomis, Joan J. Guinovart and Jesus Avila
Affiliation:
Keywords: tau kinase, GSK3 inhibition, insulin degrading enzyme (IDE), glycogen synthase (GS), Alzheimer, ’, s disease
Abstract: One of the main pathological characteristics of Alzheimers disease is the presence in the brain of the patients of an aberrant structure, the paired helical filaments, composed of hyperphosphorylated tau. The level of tau phosphorylation has been correlated with the capacity for tau aggregation. Thus, the mechanism for tau phosphorylation could be important to clarify those pathological features in Alzheimers disease. Tau protein could be modified by different kinases, being GSK3 the one that could modify more sites of that protein. GSK3 activity could be modulate by the presence of metals like magnesium that can be required for the proper function of the kinase, whereas, metals like manganesum or lithium inhibit the activity of the kinase. Many works have been done to study the inhibition of GSK3 by lithium, a specific inhibitor of that kinase. More recently, it has been indicated that sodium tungstate could also inhibit GSK3 through a different mechanism. In this review, we discuss the effect of these two metals, lithium and tungstate, on GSK3 (or tau I kinase) activity.
Export Options
About this article
Cite this article as:
Gomez-Ramos Alberto, Dominguez Jorge, Zafra Delia, Corominola Helena, Gomis Ramon, Guinovart J. Joan and Avila Jesus, Inhibition of GSK3 Dependent Tau Phosphorylation by Metals, Current Alzheimer Research 2006; 3 (2) . https://dx.doi.org/10.2174/156720506776383059
DOI https://dx.doi.org/10.2174/156720506776383059 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cells of the Macrophage Lineage and their Role in the Pathogenesis of HIV-1 Infection: An Update
Medicinal Chemistry Reviews - Online (Discontinued) The Key Role of Membranes in Amyloid Formation from a Biophysical Perspective
Current Protein & Peptide Science Salvia species, Interesting Plants Offering Perspectives in Alzheimer’s Disease
Current Traditional Medicine Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
Current Pharmaceutical Design Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets Antiplatelet Therapy and Oral Anticoagulation for Prevention of Ischemic Stroke
Current Drug Therapy Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design Dynamic Simulation, Docking and DFT Studies Applied to a Set of Anti-Acetylcholinesterase Inhibitors in the enzyme β-Secretase (BACE-1): An Important Therapeutic Target in Alzheimer's Disease
Current Computer-Aided Drug Design Epigenetic Drugs for Multiple Sclerosis
Current Neuropharmacology Biocatalysis in the Pharmaceutical Industry. A Greener Future
Current Green Chemistry Evidence for an Immune Role on Cognition in Schizophrenia: A Systematic Review
Current Neuropharmacology Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies
Current Diabetes Reviews Screening for New Agonists Against Alzheimers Disease
Medicinal Chemistry Noninvasive Assessment of Cytokines in Occupational Respiratory Diseases
Recent Patents on Inflammation & Allergy Drug Discovery The Role of Cannabinoids in Inflammatory Modulation of Allergic Respiratory Disorders, Inflammatory Pain and Ischemic Stroke
Current Drug Targets Cognitive Impairment with Vascular Impairment and Degeneration
Current Neurovascular Research The Usefulness of Amyloid Imaging in Predicting the Clinical Outcome After Two Years in Subjects with Mild Cognitive Impairment
Current Alzheimer Research Body-centred and Object-centred Motor Imagery in Alzheimer's Disease
Current Alzheimer Research Statins and Thrombin
Current Drug Targets - Cardiovascular & Hematological Disorders Synergistic Effect of L-Carnosine and EGCG in the Prevention of Physiological Brain Aging
Current Pharmaceutical Design